Giuseppe Lo Russo

4.8k total citations
145 papers, 2.0k citations indexed

About

Giuseppe Lo Russo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Giuseppe Lo Russo has authored 145 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Giuseppe Lo Russo's work include Cancer Immunotherapy and Biomarkers (47 papers), Lung Cancer Treatments and Mutations (47 papers) and Lung Cancer Research Studies (32 papers). Giuseppe Lo Russo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (47 papers), Lung Cancer Treatments and Mutations (47 papers) and Lung Cancer Research Studies (32 papers). Giuseppe Lo Russo collaborates with scholars based in Italy, United States and Spain. Giuseppe Lo Russo's co-authors include Marina Chiara Garassino, Claudia Proto, Diego Signorelli, Filippo de Braud, Federica Tomao, Roberto Ferrara, Monica Ganzinelli, Giulia Galli, Martina Imbimbo and Nicoletta Zilembo and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Giuseppe Lo Russo

137 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giuseppe Lo Russo Italy	24	1.3k	731	567	371	232	145	2.0k
Kai Li China	23	1.2k 0.9×	675 0.9×	477 0.8×	341 0.9×	242 1.0×	95	1.8k
Giulia Pasello Italy	23	1.1k 0.8×	1.1k 1.5×	510 0.9×	349 0.9×	207 0.9×	165	2.0k
Mayu Yunokawa Japan	25	1.1k 0.9×	482 0.7×	511 0.9×	373 1.0×	130 0.6×	140	2.1k
Jesús García-Donás Spain	21	787 0.6×	557 0.8×	638 1.1×	430 1.2×	181 0.8×	116	1.7k
Shigeki Umemura Japan	24	1.2k 0.9×	841 1.2×	633 1.1×	245 0.7×	334 1.4×	112	2.0k
Michele Aieta Italy	24	1.2k 0.9×	997 1.4×	638 1.1×	600 1.6×	192 0.8×	116	2.3k
Wade T. Iams United States	21	1.4k 1.1×	718 1.0×	806 1.4×	514 1.4×	308 1.3×	95	2.2k
Pol Specenier Belgium	21	1.1k 0.8×	542 0.7×	624 1.1×	261 0.7×	115 0.5×	84	1.9k
Sebastiano Buti Italy	26	1.1k 0.9×	1.2k 1.6×	690 1.2×	485 1.3×	153 0.7×	210	2.2k
Óscar Juan Spain	22	1.4k 1.1×	1.3k 1.8×	526 0.9×	378 1.0×	204 0.9×	154	2.2k

Countries citing papers authored by Giuseppe Lo Russo

Since Specialization

Citations

This map shows the geographic impact of Giuseppe Lo Russo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Lo Russo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Lo Russo more than expected).

Fields of papers citing papers by Giuseppe Lo Russo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppe Lo Russo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Lo Russo. The network helps show where Giuseppe Lo Russo may publish in the future.

Co-authorship network of co-authors of Giuseppe Lo Russo

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppe Lo Russo. A scholar is included among the top collaborators of Giuseppe Lo Russo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppe Lo Russo. Giuseppe Lo Russo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Majem, Margarita, Vanesa Gregorc, Giuseppe Lo Russo, et al.. (2025). LBA1: First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 20(3). S1–S1.

Proto, Claudia, Giuseppe Lo Russo, Arsela Prelaj, et al.. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 9(9). e2400790–e2400790. 1 indexed citations

Pongiglione, Benedetta, Maria Cucciniello, Francesco Petracca, et al.. (2025). A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial. Supportive Care in Cancer. 33(7). 641–641.

Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations

Occhipinti, Mario, Marta Brambilla, Raimondo Di Liello, et al.. (2024). Unleashing precision: A review of targeted approaches in pleural mesothelioma. Critical Reviews in Oncology/Hematology. 203. 104481–104481. 6 indexed citations

Leporati, Rita, Laura Mazzeo, Sara Manglaviti, et al.. (2024). Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs. Tumori Journal. 110(6). NP1–NP4. 2 indexed citations

Lu, Shun, Fabrice Barlési, Robert M. Jotte, et al.. (2024). OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12. Journal of Thoracic Oncology. 19(10). S30–S30. 2 indexed citations

Lorenzini, Daniele, A. Bassetti, Elena Tamborini, et al.. (2024). Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. Clinical Lung Cancer. 26(1). e11–e17. 1 indexed citations

Lorenzini, Daniele, Mario Occhipinti, Sara Manglaviti, et al.. (2023). 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib. Annals of Oncology. 34. S779–S779. 1 indexed citations

10.

Zattarin, Emma, Sara Manglaviti, Laura Mazzeo, et al.. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncology. 18(23). 2593–2604. 3 indexed citations

11.

Ferrara, Roberto, Giuseppe Lo Russo, Chiara Maura Ciniselli, et al.. (2022). 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations. Annals of Oncology. 33. S1038–S1038. 1 indexed citations

12.

Ferrara, Roberto, Diego Signorelli, Claudia Proto, et al.. (2021). Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Translational Lung Cancer Research. 10(6). 2955–2969. 6 indexed citations

13.

Toma, Alessandro De, Giuseppe Lo Russo, Diego Signorelli, et al.. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology. 160. 103299–103299. 5 indexed citations

14.

Miceli, Rosalba, Hanna Eriksson, Alex J. Eustace, et al.. (2021). 1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment. Annals of Oncology. 32. S1223–S1224. 4 indexed citations

15.

Occhipinti, Mario, Marta Brambilla, Giulia Galli, et al.. (2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 11(5). 424–424. 8 indexed citations

16.

Prinzi, Natalie, Roberta Rossi, Claudia Proto, et al.. (2020). Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clinical Lung Cancer. 22(3). 161–169. 15 indexed citations

17.

Boeri, Mattia, Massimo Milione, Claudia Proto, et al.. (2019). Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clinical Cancer Research. 25(7). 2166–2173. 64 indexed citations

18.

Cavalieri, Stefano, Alessandra Raimondi, Daniele Morelli, et al.. (2016). Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging. Annals of Oncology. 27. iv13–iv13. 1 indexed citations

19.

Califano, Raffaele, Keith M. Kerr, Robert D. Morgan, et al.. (2016). Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Current Oncology Reports. 18(9). 59–59. 29 indexed citations

20.

Silingardi, V., et al.. (1981). The Radiologic ‘Target Sign’ of Septic Pulmonary Embolism in a Case of Acute Myelogenous Leukemia. Respiration. 42(1). 61–66. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact